Browsing Tag
Rocatinlimab
3 posts
Why did Amgen Inc. walk away from its $1.25bn eczema drug deal with Kyowa Kirin?
Amgen Inc. exits its $1.25B eczema drug deal with Kyowa Kirin Co., Ltd., reshaping its immunology focus. Find out what this move means for both companies’ pipelines.
Amgen and Kyowa Kirin report Phase 3 rocatinlimab results highlighting long-term safety and durable response in atopic dermatitis
Amgen and Kyowa Kirin report Phase 3 rocatinlimab results showing long-term safety and durable efficacy in atopic dermatitis. Find out what comes next.
Amgen and Kyowa Kirin see breakthrough in rocatinlimab Phase 3 Trial, eyes on FDA path
Amgen and Kyowa Kirin have reported positive top-line results from the Rocatinlimab Phase 3 IGNITE trial, part of…